GlaxoSmithKline PLC's Salford Lung Study of its Relvar/Breo Ellipta inhaler in chronic obstructive pulmonary disease breaks new ground as a prospective, randomized, controlled trial in everyday health care practice started prior to launch, though analysts question the commercial impact.
The Phase IIIb Salford Lung Study was designed as a real world safety and efficacy study of the once-daily product,...